rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.
|
21483012 |
2011 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
V599E BRAF mutation was uncommon in Japanese lung cancer.
|
16376942 |
2006 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Success of this design of clinical trials and practice was first demonstrated in EGFR inhibitor trials in lung cancer and has since been incorporated into subsequent targeted therapy trials including ALK-, ROS1-, and BRAF V600E-targeted therapies.
|
28786099 |
2017 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer.
|
29348459 |
2018 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.
|
21483012 |
2011 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer.
|
29348459 |
2018 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
V599E BRAF mutation was uncommon in Japanese lung cancer.
|
16376942 |
2006 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Success of this design of clinical trials and practice was first demonstrated in EGFR inhibitor trials in lung cancer and has since been incorporated into subsequent targeted therapy trials including ALK-, ROS1-, and BRAF V600E-targeted therapies.
|
28786099 |
2017 |
rs1225976306
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |
rs868021367
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Of the 13 genotypes, 4 genotypes (G464E, G596R, A598T, and G606R) had not been previously reported in lung cancer.
|
24297085 |
2014 |